Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Completed · Phase 2 · NCT04154943
Conditions: Cutaneous Squamous Cell Carcinoma
At a glance
- Research payments reported, 2025
- $308,458
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 79
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Cemiplimab (drug)
- Dates
- Started 2020-03-10; completion 2025-11-19
- Results posted
- Yes
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review. The secondary objectives of the study are: * To evaluate the efficacy of neoadjuvant cemiplimab on measures of disease response, including: * Major pathologic response (mPR) rate per independent central pathology review * pCR rate and mPR rate per local pathology review * ORR prior to surgery, according to local assessment using RECIST 1.1 * To evaluate the efficacy of neoadjuvant cemiplimab on event free survival (EFS), disease free survival (DFS), and overall survival (OS) * To evaluate the safety profil…
From ClinicalTrials.gov, last updated 2025-12-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $308,458 in research payments for this study in 2025 (53 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vasu Divi, MD Facial Plastic Surgery · Stanford, CA
- David L. Miller, M.D. Pulmonology · Boston, MA
- Evan J. Lipson, MD Medical Oncology · Baltimore, MD
- Paul L. Swiecicki, MD Medical Oncology · Ann Arbor, MI
- April K. Salama, M.D. Internal Medicine · Durham, NC
- Nikhil I. Khushalani, MD MBBS Medical Oncology · Buffalo, NY
- Jessica L. Geiger, MD Medical Oncology · Cleveland, OH
- Vishal A. Patel, MD Dermatology · Lansdowne, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $105,883
- Cleveland Clinic, OH $76,590
- Stanford University $53,230
- University of Michigan Health System, MI $28,927
- Moffitt Cancer Center $16,258
- Johns Hopkins University $16,077
- Dana Farber Mass General Brigham Cancer Care Inc $10,010
- Medical Faculty Associates Inc $1,483
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.